Palisade bio announces positive preclinical data of lead program pali-2108 at the 2024 crohn's & colitis congress

– preclinical data demonstrated pali-2108 to be safe and well tolerated – pali-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – company advancing pali-2108 for the treatment of moderate-to-severe ulcerative colitis (uc) toward phase 1 clinical study, expected to commence in 2024 carlsbad, ca, jan. 29, 2024 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (“palisade” or the “company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (gi) diseases, today announced the presentation of positive preclinical data of its lead asset, pali-2108 at the crohn's & colitis congress, which was held on january 25-27, 2024 in las vegas, nv. the preclinical data was presented in a poster titled, local bioactivation and efficacy of pali-2108: a promising pde4 inhibitor prodrug for ulcerative colitis treatment.
PALI Ratings Summary
PALI Quant Ranking